Lemtrada research continues to back this MS medication.
Two short courses of Lemtrada (alemtuzumab) prevented multiple sclerosis from becoming active and progressing for five years, a study reported.
Lemtrada’s maker, Sanofi-Genzyme, said the study covered the two-year CARE-MS II Phase 3 clinical trial (NCT00548405) and a long-term extension (NCT00930553) trial of people with relapsing-remitting MS.
In addition to demonstrating Lemtrada’s effectiveness, the study showed that it was safe, researchers said.
Read full article: MS Progression Halted Over Five Years by Lemtrada, Study Reports
|Read Full Article: MS Progression Halted Over Five Years by Lemtrada, Study Reports|